$RARE
Ultragenyx Pharmaceutical Inc. Stock $rare

$rare Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-K Financial Statement

#000095017022001284 Filed on February 15, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021
Revenue	$79.94M	$83.39M	$351.4M
YoY Change	-19.58%	-8.91%	29.66%
Cost Of Revenue	$6.100M	$3.509M	$16.01M
YoY Change	17.53%	-35.97%	162.43%
Gross Profit	$73.84M	$79.88M	$335.4M
YoY Change	-21.63%	-7.18%	26.61%
Gross Profit Margin	92.37%	95.79%	95.44%
Selling, General & Admin	$67.31M	$59.43M	$220.0M
YoY Change	26.39%	16.44%	20.25%
% of Gross Profit	91.17%	74.4%	65.59%
Research & Development	$143.2M	$123.0M	$497.2M
YoY Change	-2.96%	-6.17%	20.64%
% of Gross Profit	193.89%	154.0%	148.23%
Depreciation & Amortization	$4.088M	$3.534M	$13.24M
YoY Change	21.41%	12.91%	7.98%
% of Gross Profit	5.54%	4.42%	3.95%
Operating Expenses	$210.5M	$182.4M	$717.1M
YoY Change	4.83%	-2.76%	20.52%
Operating Profit	-$136.6M	-$102.6M	-$381.7M
YoY Change	28.21%	0.99%	15.64%
Interest Expense	-$8.835M	-$15.66M	-$40.14M
YoY Change	-55.78%	-119.57%	-122.62%
% of Operating Profit
Other Income/Expense, Net	$289.0K	-$4.214M	-$1.687M
YoY Change	-136.35%	-46.66%	-377.92%
Pretax Income	-$151.8M	-$122.4M	-$453.0M
YoY Change	11.79%	411.44%	144.38%
Income Tax	$558.0K	$20.00K	$1.044M
% Of Pretax Income
Net Earnings	-$152.3M	-$122.5M	-$454.0M
YoY Change	11.88%	410.01%	143.36%
Net Earnings / Revenue	-190.55%	-146.85%	-129.2%
Basic Earnings Per Share	-$2.19		-$6.70
Diluted Earnings Per Share	-$2.191M	-$1.786M	-$6.697M
COMMON SHARES
Basic Shares Outstanding	69.38M	68.16M	67.80M
Diluted Shares Outstanding	69.52M		67.80M

Balance Sheet

Concept	2022 Q1	2021 Q4	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$598.3M	$740.2M	$740.2M
YoY Change	-38.02%	-38.4%	-38.39%
Cash & Equivalents	$154.0M	$307.6M	$307.6M
Short-Term Investments	$444.3M	$432.6M	$432.6M
Other Short-Term Assets	$63.02M	$71.75M	$71.75M
YoY Change	-7.32%	24.56%	24.56%
Inventory	$17.81M	$16.23M	$16.23M
Prepaid Expenses
Receivables	$28.37M	$28.43M	$28.43M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$707.5M	$856.6M	$856.6M
YoY Change	-33.93%	-33.87%	-33.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$177.1M	$141.2M	$176.2M
YoY Change	40.42%	92.13%	54.55%
Goodwill	$44.41M	$44.41M
YoY Change		0.0%
Intangibles	$160.0M	$130.8M
YoY Change		-0.25%
Long-Term Investments	$241.1M	$293.9M	$293.9M
YoY Change	11.42%	77.13%	77.13%
Other Assets	$21.22M	$20.56M	$20.56M
YoY Change	138.4%	133.3%	133.61%
Total Long-Term Assets	$676.5M	$665.8M	$665.8M
YoY Change	28.39%	43.41%	43.4%
TOTAL ASSETS
Total Short-Term Assets	$707.5M	$856.6M	$856.6M
Total Long-Term Assets	$676.5M	$665.8M	$665.8M
Total Assets	$1.384B	$1.522B	$1.522B
YoY Change	-13.38%	-13.48%	-13.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$23.69M	$17.14M	$17.14M
YoY Change	50.86%	32.62%	32.85%
Accrued Expenses	$126.4M	$145.6M	$156.1M
YoY Change	52.79%	34.16%	33.38%
Deferred Revenue	$5.867M	$9.076M
YoY Change	-76.62%	-86.37%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$568.0K	$568.0K
YoY Change		13.6%	13.6%
Total Short-Term Liabilities	$167.2M	$181.4M	$181.4M
YoY Change	31.68%	-4.35%	-4.34%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$410.0K	$410.0K
YoY Change		-41.43%	-41.43%
Other Long-Term Liabilities	$3.392M	$1.005M	$384.8M
YoY Change	-99.11%	-86.32%	0.83%
Total Long-Term Liabilities	$3.392M	$1.005M	$385.2M
YoY Change	-99.11%	-86.32%	0.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$167.2M	$181.4M	$181.4M
Total Long-Term Liabilities	$3.392M	$1.005M	$385.2M
Total Liabilities	$587.6M	$599.8M	$599.8M
YoY Change	8.17%	-0.88%	-0.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.226B	-$2.074B
YoY Change		28.03%
Common Stock	$70.00K	$69.00K
YoY Change		2.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$796.4M	$922.6M	$922.6M
YoY Change
Total Liabilities & Shareholders Equity	$1.384B	$1.522B	$1.522B
YoY Change	-13.38%	-13.48%	-13.48%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021
OPERATING ACTIVITIES
Net Income	-$152.3M	-$122.5M	-$454.0M
YoY Change	11.88%	410.01%	143.36%
Depreciation, Depletion And Amortization	$4.088M	$3.534M	$13.24M
YoY Change	21.41%	12.91%	7.98%
Cash From Operating Activities	-$117.5M	-$54.34M	-$338.7M
YoY Change	-26.25%	-12.98%	156.16%
INVESTING ACTIVITIES
Capital Expenditures	$32.18M	-$16.05M	$73.09M
YoY Change	96.08%	-18.46%	66.48%
Acquisitions			$0.00
YoY Change
Other Investing Activities	-$2.578M	$85.10M	$942.0K
YoY Change	-98.45%	-27.61%	-83.04%
Cash From Investing Activities	-$37.36M	$69.06M	-$195.4M
YoY Change	-79.52%	-29.46%	9.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.612M	85.73M	118.6M
YoY Change	-87.26%	-82.49%	-80.25%
NET CHANGE
Cash From Operating Activities	-117.5M	-54.34M	-338.7M
Cash From Investing Activities	-37.36M	69.06M	-195.4M
Cash From Financing Activities	1.612M	85.73M	118.6M
Net Change In Cash	-153.4M	100.4M	-416.7M
YoY Change	-53.51%	-80.87%	-243.67%
FREE CASH FLOW
Cash From Operating Activities	-$117.5M	-$54.34M	-$338.7M
Capital Expenditures	$32.18M	-$16.05M	$73.09M
Free Cash Flow	-$149.7M	-$38.30M	-$411.8M
YoY Change	-14.82%	-10.46%	133.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherNoncurrentAssetsMember
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Current Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PrepaidExpensesAndOtherCurrentAssetsMember
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.ultragenyx.com/20211231#OperatingAndFinanceLeaseLiabilityNoncurrent
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherNoncurrentAssetsMember
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.ultragenyx.com/20211231#OperatingAndFinanceLeaseLiabilityCurrent
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Current Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PrepaidExpensesAndOtherCurrentAssetsMember
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.ultragenyx.com/20211231#OperatingAndFinanceLeaseLiabilityNoncurrent
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherNoncurrentAssetsMember
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001515673
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.ultragenyx.com/20211231#OperatingAndFinanceLeaseLiabilityCurrent
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Current Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PrepaidExpensesAndOtherCurrentAssetsMember
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-36276
CY2021	dei	Entity Registrant Name EntityRegistrantName	Ultragenyx Pharmaceutical Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-2546083
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	60 Leveroni Court
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Novato
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94949
CY2021	dei	City Area Code CityAreaCode	415
CY2021	dei	Local Phone Number LocalPhoneNumber	483-8800
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2021	dei	Trading Symbol TradingSymbol	RARE
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q2	dei	Entity Public Float EntityPublicFloat	6500000000
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	69384774
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Redwood City, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	307584000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	713526000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	432612000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	488007000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28432000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23093000
CY2021Q4	us-gaap	Inventory Net InventoryNet	16231000
CY2020Q4	us-gaap	Inventory Net InventoryNet	13048000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	71745000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	57630000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	856604000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	1295304000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	141247000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	73515000
CY2021Q4	rare	Equity Investments Noncurrent EquityInvestmentsNoncurrent	34925000
CY2020Q4	rare	Equity Investments Noncurrent EquityInvestmentsNoncurrent	155375000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	258933000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	10506000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	34936000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	40524000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	130788000
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	131113000
CY2021Q4	us-gaap	Goodwill Goodwill	44406000
CY2020Q4	us-gaap	Goodwill Goodwill	44406000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20558000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8812000
CY2021Q4	us-gaap	Assets Assets	1522397000
CY2020Q4	us-gaap	Assets Assets	1759555000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17138000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12923000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	145555000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	108491000
CY2021Q4	rare	Contract Liabilities Current ContractLiabilitiesCurrent	7609000
CY2020Q4	rare	Contract Liabilities Current ContractLiabilitiesCurrent	59219000
CY2021Q4	rare	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	11066000
CY2020Q4	rare	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	8976000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	181368000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	189609000
CY2021Q4	rare	Contract Liabilities Noncurrent ContractLiabilitiesNoncurrent	1467000
CY2020Q4	rare	Contract Liabilities Noncurrent ContractLiabilitiesNoncurrent	7349000
CY2021Q4	rare	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	30904000
CY2020Q4	rare	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	39251000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	33306000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	33306000
CY2021Q4	rare	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	351786000
CY2020Q4	rare	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	335665000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1005000
CY2021Q4	us-gaap	Liabilities Liabilities	599836000
CY2020Q4	us-gaap	Liabilities Liabilities	605180000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69344998
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69344998
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	66818520
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	66818520
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	69000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	67000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2997497000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2773195000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1404000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	689000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2073601000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1619576000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	922561000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1154375000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1522397000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1759555000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	351406000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	271030000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	103714000
CY2021	rare	Cost Of Sales CostOfSales	16008000
CY2020	rare	Cost Of Sales CostOfSales	6129000
CY2019	rare	Cost Of Sales CostOfSales	9008000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	497153000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	412084000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	357355000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	219982000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	182933000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	161524000
CY2021	rare	Cost Of Sales And Operating Expenses CostOfSalesAndOperatingExpenses	733143000
CY2020	rare	Cost Of Sales And Operating Expenses CostOfSalesAndOperatingExpenses	601146000
CY2019	rare	Cost Of Sales And Operating Expenses CostOfSalesAndOperatingExpenses	527887000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-381737000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-330116000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-424173000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	1928000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	7038000
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	13238000
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-42063000
CY2020	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	170403000
CY2019	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	13413000
CY2021	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	29422000
CY2020	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	33291000
CY2019	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	1135000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1687000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	607000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-787000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-452981000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-185359000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-402727000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	653764000
CY2020	rare	Stock Issued During Period Value Secondary Issues StockIssuedDuringPeriodValueSecondaryIssues	435556000
CY2020	rare	Issuance Of Common Stock Value In Connection With License Agreement IssuanceOfCommonStockValueInConnectionWithLicenseAgreement	55268000
CY2020	rare	Stock Issued During Period Value At Market Offering StockIssuedDuringPeriodValueAtMarketOffering	20391000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	85833000
CY2020	rare	Issuance Of Common Stock Upon Exercise Of Warrants And Under Equity Plan Awards Net Of Tax IssuanceOfCommonStockUponExerciseOfWarrantsAndUnderEquityPlanAwardsNetOfTax	89293000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	836000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-399444000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1044000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1207000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3283000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-454025000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-186566000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-402727000
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.70
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.07
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-7.12
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67795540
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	60845550
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	56576885
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-454025000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-186566000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-402727000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-550000
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	735000
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	23000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1543000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	101000
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	463000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2093000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	836000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	486000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-456118000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-185730000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-402241000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	608908000
CY2019	rare	Stock Issued During Period Value Secondary Issues StockIssuedDuringPeriodValueSecondaryIssues	330415000
CY2019	rare	Stock Issued During Period Value At Market Offering StockIssuedDuringPeriodValueAtMarketOffering	24828000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	82025000
CY2019	rare	Issuance Of Common Stock Under Equity Plan Awards Net Of Tax IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax	9829000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	486000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-186566000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1154375000
CY2021	rare	Stock Issued During Period Value At Market Offering StockIssuedDuringPeriodValueAtMarketOffering	78943000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	105260000
CY2021	rare	Issuance Of Common Stock Under Equity Plan Awards Net Of Tax IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax	40101000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2093000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-454025000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	922561000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-454025000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-186566000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-402727000
CY2021	rare	Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost AllocatedShareBasedCompensationExpenseNetOfCapitalizedInventoryCost	104952000
CY2020	rare	Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost AllocatedShareBasedCompensationExpenseNetOfCapitalizedInventoryCost	85735000
CY2019	rare	Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost AllocatedShareBasedCompensationExpenseNetOfCapitalizedInventoryCost	81995000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-6606000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-848000
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	6214000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13239000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12261000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8539000
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-42063000
CY2020	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	170403000
CY2019	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	13413000
CY2021	rare	Non Cash Collaboration Royalty Revenue NonCashCollaborationRoyaltyRevenue	17951000
CY2020	rare	Non Cash Collaboration Royalty Revenue NonCashCollaborationRoyaltyRevenue	12995000
CY2021	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	29422000
CY2020	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	33291000
CY2019	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	1135000
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-235000
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-946000
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2621000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5432000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9840000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	20104000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3117000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1346000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4451000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	29508000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2748000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8216000
CY2021	rare	Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherOperatingLiabilities	32313000
CY2020	rare	Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherOperatingLiabilities	26853000
CY2019	rare	Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherOperatingLiabilities	13312000
CY2021	rare	Increase Decrease In Contract Liabilities IncreaseDecreaseInContractLiabilities	-57492000
CY2020	rare	Increase Decrease In Contract Liabilities IncreaseDecreaseInContractLiabilities	66568000
CY2019	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	2140000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-338695000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-132220000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-345383000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	73093000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	43905000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24832000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1012187000
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	813237000
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	692824000
CY2020	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	37062000
CY2019	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	14339000
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	92896000
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	50990000
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	42718000
CY2021	rare	Proceeds From Sale Of Equity Investment ProceedsFromSaleOfEquityInvestment	79843000
CY2020	rare	Proceeds From Sale Of Equity Investment ProceedsFromSaleOfEquityInvestment	79842000
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	718111000
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	589806000
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	676238000
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	942000
CY2020	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	5555000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-195372000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-179121000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13039000
CY2019	rare	Proceeds From Royalties Received Financing Activities ProceedsFromRoyaltiesReceivedFinancingActivities	314234000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	435556000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	330415000
CY2020	rare	Proceeds From Issuance Of Common Stock In Connection With License Agreement ProceedsFromIssuanceOfCommonStockInConnectionWithLicenseAgreement	55268000
CY2021	rare	Proceeds From Issuance Of Common Stock At Market Offering ProceedsFromIssuanceOfCommonStockAtMarketOffering	78943000
CY2020	rare	Proceeds From Issuance Of Common Stock At Market Offering ProceedsFromIssuanceOfCommonStockAtMarketOffering	20391000
CY2019	rare	Proceeds From Issuance Of Common Stock At Market Offering ProceedsFromIssuanceOfCommonStockAtMarketOffering	24828000
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	40101000
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	89293000
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	9829000
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-492000
CY2020	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-236000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	118552000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	600272000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	679306000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1194000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1119000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-165000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-416709000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	290050000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	320719000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	726294000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	436244000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	115525000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	309585000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	726294000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	436244000
CY2021	rare	Operating And Finance Lease Liability From Obtaining Right Of Use Assets OperatingAndFinanceLeaseLiabilityFromObtainingRightOfUseAssets	3142000
CY2020	rare	Operating And Finance Lease Liability From Obtaining Right Of Use Assets OperatingAndFinanceLeaseLiabilityFromObtainingRightOfUseAssets	18775000
CY2019	rare	Operating And Finance Lease Liability From Obtaining Right Of Use Assets OperatingAndFinanceLeaseLiabilityFromObtainingRightOfUseAssets	21861000
CY2021	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1453000
CY2020	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1304000
CY2019	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1206000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	18993000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	8515000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10367000
CY2021	rare	Non Cash Interest Expense On Liability Related To The Sale Of Future Royalties Capitalized Into Ending Property Plant And Equipment NonCashInterestExpenseOnLiabilityRelatedToTheSaleOfFutureRoyaltiesCapitalizedIntoEndingPropertyPlantAndEquipment	4650000
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of the Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, income taxes, stock-based compensation, and the liability related to the sale of future royalties. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	307584000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	713526000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	433584000
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	10847000
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	161000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2001000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1921000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2499000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	309585000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	726294000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	436244000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	1001451000
CY2020Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	1327662000
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	969592000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1288000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	968309000
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1172646000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	277000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	17000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1172906000
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	10504000
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	7184000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5727000
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5864000
CY2021Q4	us-gaap	Inventory Net InventoryNet	16231000
CY2020Q4	us-gaap	Inventory Net InventoryNet	13048000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	191285000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	110907000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	50038000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	37392000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	141247000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	73515000
CY2021	rare	Depreciation Excluding Intangible Amortization DepreciationExcludingIntangibleAmortization	12900000
CY2020	rare	Depreciation Excluding Intangible Amortization DepreciationExcludingIntangibleAmortization	12100000
CY2019	rare	Depreciation Excluding Intangible Amortization DepreciationExcludingIntangibleAmortization	8300000
CY2021Q4	rare	Research Clinical Study And Manufacturing Expenses ResearchClinicalStudyAndManufacturingExpenses	40880000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	103714000
CY2020Q4	rare	Research Clinical Study And Manufacturing Expenses ResearchClinicalStudyAndManufacturingExpenses	25875000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	62591000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	58176000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	42084000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	24440000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	145555000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	108491000
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	351406000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	271030000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	351406000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	271030000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	103714000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	66568000
CY2021	rare	Contract With Customer Liability Additions During Period ContractWithCustomerLiabilityAdditionsDuringPeriod	-27504000
CY2020	rare	Contract With Customer Liability Additions During Period ContractWithCustomerLiabilityAdditionsDuringPeriod	-155788000
CY2021	rare	Contract With Customer Liability Deductions During Period ContractWithCustomerLiabilityDeductionsDuringPeriod	-84996000
CY2020	rare	Contract With Customer Liability Deductions During Period ContractWithCustomerLiabilityDeductionsDuringPeriod	-89220000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	9076000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	66568000
CY2021Q4	rare	Percentage Of Gross Accounts Receivable Balance PercentageOfGrossAccountsReceivableBalance	0.71
CY2020Q4	rare	Percentage Of Gross Accounts Receivable Balance PercentageOfGrossAccountsReceivableBalance	0.71
CY2021	rare	Lessee Operating Lease Expiry Year LesseeOperatingLeaseExpiryYear	2028
CY2021	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2021	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	multiple renewal periods
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	11209000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	10164000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	4142000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	3298000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	310000
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	158000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	58000
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	40000
CY2021	us-gaap	Lease Cost LeaseCost	15719000
CY2020	us-gaap	Lease Cost LeaseCost	13660000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	11800000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	12873000
CY2021Q4	rare	Operating And Finance Lease Liability Due After Year Five OperatingAndFinanceLeaseLiabilityDueAfterYearFive	776000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	46741000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	1030000
CY2021Q4	rare	Operating And Finance Lease Liability Payments Due OperatingAndFinanceLeaseLiabilityPaymentsDue	47771000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5749000
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	52000
CY2021Q4	rare	Operating And Finance Lease Liability Undiscounted Excess Amount OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount	5801000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	40992000
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	978000
CY2021	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties And Capitalized To Property Plant And Equipment NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyaltiesAndCapitalizedToPropertyPlantAndEquipment	34072000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	606000
CY2021Q4	rare	Operating And Finance Lease Liability Payments Due Next Twelve Months OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths	13479000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	13072000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	349000
CY2021Q4	rare	Operating And Finance Lease Liability Payments Due Year Two OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo	13421000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	11092000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	75000
CY2021Q4	rare	Operating And Finance Lease Liability Payments Due Year Three OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree	11167000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6247000
CY2021Q4	rare	Operating And Finance Lease Liability Payments Due Year Four OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour	6247000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2681000
CY2021Q4	rare	Operating And Finance Lease Liability Payments Due Year Five OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive	2681000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	776000
CY2021Q4	rare	Operating And Finance Lease Liability OperatingAndFinanceLeaseLiability	41970000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10498000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	568000
CY2021Q4	rare	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	11066000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30494000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	410000
CY2021Q4	rare	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	30904000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M2D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M17D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0664
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0544
CY2019Q4	rare	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	315369000
CY2020	rare	Non Cash Collaboration Royalty Revenue NonCashCollaborationRoyaltyRevenue	12995000
CY2020	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties And Capitalized To Property Plant And Equipment NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyaltiesAndCapitalizedToPropertyPlantAndEquipment	33291000
CY2020Q4	rare	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	335665000
CY2021	rare	Non Cash Collaboration Royalty Revenue NonCashCollaborationRoyaltyRevenue	17951000
CY2021Q4	rare	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	351786000
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	63.03
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	235678
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	32.87
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	766457
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	72.48
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6113064
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	62.51
CY2021	rare	Stock Issued During Period Shares At Market Offering StockIssuedDuringPeriodSharesAtMarketOffering	1050372
CY2021	rare	Proceeds From Issuance Of Common Stock At Market Offering ProceedsFromIssuanceOfCommonStockAtMarketOffering	78900000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5353124
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	62.46
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M19D
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	23243000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1762075
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	18989000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1849106
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	62.51
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1505486
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	58.51
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	452081
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	69.38
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6004603
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	62.99
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M15D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	453253000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1217820
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	128.63
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	687835
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	53.14
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	336383
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	81.78
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6198205
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	75.96
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M21D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	112242000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3669577
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	64.93
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y7M28D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	80283000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5951372
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	75.09
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y8M23D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	109665000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	38300000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	56900000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	6500000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	36600000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	88100000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7700000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	70.84
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	35.22
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	37.15
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	48100000
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	45400000
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	45300000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	104979000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	85735000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	81995000
CY2021	rare	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount Including Amount Expensed To Cost Of Goods Sold EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmountIncludingAmountExpensedToCostOfGoodsSold	1700000
CY2020	rare	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount Including Amount Expensed To Cost Of Goods Sold EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmountIncludingAmountExpensedToCostOfGoodsSold	1200000
CY2019	rare	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount Including Amount Expensed To Cost Of Goods Sold EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmountIncludingAmountExpensedToCostOfGoodsSold	1400000
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	200000000.0
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M29D
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	5500000
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4300000
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3600000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-455314000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-189449000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-399709000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	2333000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	4090000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	265000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-452981000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-185359000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-399444000
CY2021	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-14000
CY2020	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	15000
CY2019	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	51000
CY2021	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	1058000
CY2020	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	1192000
CY2019	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	1092000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1044000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1207000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1143000
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	2140000
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2140000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1044000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1207000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3283000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.005
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.072
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.137
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.052
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.005
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.005
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.002
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary	0.022
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.008
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.009
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.004
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.013
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.009
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.010
CY2021	rare	Effective Income Tax Rate Reconciliation Change In Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions	-0.014
CY2020	rare	Effective Income Tax Rate Reconciliation Change In Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions	-0.027
CY2019	rare	Effective Income Tax Rate Reconciliation Change In Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions	-0.010
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.279
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.339
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.236
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.005
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.003
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.007
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.008
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	306119000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	222902000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	218131000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	184961000
CY2021Q4	rare	Deferred Tax Assets Stock Option DeferredTaxAssetsStockOption	33564000
CY2020Q4	rare	Deferred Tax Assets Stock Option DeferredTaxAssetsStockOption	39154000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	25735000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	24922000
CY2021Q4	rare	Deferred Tax Asset Fixed Assets And Intangibles DeferredTaxAssetFixedAssetsAndIntangibles	18263000
CY2020Q4	rare	Deferred Tax Asset Fixed Assets And Intangibles DeferredTaxAssetFixedAssetsAndIntangibles	7242000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	46662000
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021Q4	rare	Deferred Tax Assets Liability Related To Sale Of Future Royalties DeferredTaxAssetsLiabilityRelatedToSaleOfFutureRoyalties	90826000
CY2020Q4	rare	Deferred Tax Assets Liability Related To Sale Of Future Royalties DeferredTaxAssetsLiabilityRelatedToSaleOfFutureRoyalties	86664000
CY2021Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	3912000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	13060000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	28642000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	709610000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	594487000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	700669000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	561139000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	8941000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	33348000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	42247000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	66654000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	33306000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	33306000
CY2011Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	200000
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	200000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	139500000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	74300000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	39954000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	33727000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	8542000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	6950000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	5575000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	356000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	382000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	652000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	200000
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	624000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	55360000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	46662000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	39954000
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67795540
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	60845550
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	56576885
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.70
CY2021Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	4100000
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.07
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-7.12
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-454025000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-186566000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-402727000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8217574
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8564311
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8132319
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1404000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	689000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-121000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	429000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1283000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	260000

Files In Submission

Name	View Source	Status
0000950170-22-001284-index-headers.html	Edgar Link	pending
0000950170-22-001284-index.html	Edgar Link	pending
0000950170-22-001284.txt	Edgar Link	pending
0000950170-22-001284-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img196301111_0.jpg	Edgar Link	pending
img214107015_0.jpg	Edgar Link	pending
img214107015_1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
rare-20211231.htm	Edgar Link	pending
rare-20211231.xsd	Edgar Link	pending
rare-20211231_cal.xml	Edgar Link	unprocessable
rare-20211231_def.xml	Edgar Link	unprocessable
rare-20211231_htm.xml	Edgar Link	completed
rare-20211231_lab.xml	Edgar Link	unprocessable
rare-20211231_pre.xml	Edgar Link	unprocessable
rare-ex10_13.htm	Edgar Link	pending
rare-ex10_20.htm	Edgar Link	pending
rare-ex21_1.htm	Edgar Link	pending
rare-ex23_1.htm	Edgar Link	pending
rare-ex31_1.htm	Edgar Link	pending
rare-ex31_2.htm	Edgar Link	pending
rare-ex32_1.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RARE
Ultragenyx Pharmaceutical Inc. Stock $rare

2022 Q1 Form 10-K Financial Statement

#000095017022001284 Filed on February 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RARE Ultragenyx Pharmaceutical Inc. Stock $rare

2022 Q1 Form 10-K Financial Statement

#000095017022001284 Filed on February 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RARE
Ultragenyx Pharmaceutical Inc. Stock $rare